DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting Jun 3, 2019
DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering May 8, 2019
